攀钢高炉焖砂口试验

分析了高炉冶练钒钛磁铁矿炉前砂口损坏的原因。对新型砂口泥进研制，同时改进了套砂口工艺，满足了攀钢高炉焖砂口的需要。攀钢高炉采用闷砂口工艺后，从根本上解决了铁水带渣问题，提高了铁水的洁净度。     

SHG对污水的处理效果

SHG对不同污水的COD的降低,DO的增加,及色、臭味和浊度的降低效果明显。     

气体悬浮焙烧炉内衬烘炉曲线的确定

根据所使用的低水泥浇注料的性能，对中铝山西分公司检修厂4号焙烧炉制定了合理的烘烤曲线，提高了耐火内衬的质量，延长了内衬的使用寿命。     

轻质喷涂料的研制

研究了轻质骨料种类，加入量和添加剂等对轻质喷涂料技术及使用性能的影响。并将研制的轻质喷涂料成功地应用于武钢炼铁厂高炉管内壁的喷涂。     

Cr_2O_3对矾土－尖晶石耐火材料抗渣性的影响

以高铝矾土及预合成电熔ＭＡ砂为原料，制各了矾土－尖晶石耐火材料。对其加入铬精矿后的抗渣性进行了试验。结果表明，少量铬精矿的加入能形成尖晶石固溶体，提高制品的抗渣性能。     

镇沅金精矿选择性固砷焙烧—氰化浸出新工艺研究

对云南镇沅金矿的难当金精矿进行了选择性固砷焙烧－氰化浸出的试验研究，取得了满意结果。砷固定率大于９２％，硫挥发率为７８％－８４％，金浸出率可达９１％－９３％。选择性固砷焙烧－氰化浸出新工艺可有效消除砷害，综合利用有价成分硫，特别适宜于含砷高硫，同时含碳等杂质的细粒浸染型难浸金矿石的处理，在我国有较大的发展前景。     

高碳铬铁电炉高基质干式打结料的研究

通过对组成打结料成分特性的研究，提出以优质原料生产的MgO-CaO-Fe2O3系合成砂为骨料，用MgO〉97％，粒度〈0．088mm烧结镁砂做细粉，适当添加超微粉等工艺措施，制成适当高碳铬铁电炉炉底用的高基质打结料，通过调控基质成分，实现材料相和固相的复合烧结。     

Anaerobic digestion of alkaline black liquor using an up-flow anaerobic sludge blanket reactor

The anaerobic digestion of alkaline black liquor from a cereal straw pulping mill was studied in batch (serum bottles) and continuous systems (up-flow anaerobic sludge blanket reactor—UASB). The batch digestion studies confirmed that lignin and related compounds (LRC) in the alkaline black liquor were the main inhibitory substances and could not be decomposed by anaerobic bacteria. At organic loading rates of 5–10 kg COD m^?3 day^?1, the UASB reactor achieved 50–60% COD removal efficiencies. Gas production was 2–3 dm³ per dm³ of alkaline black liquor. Two different sludge types were examined in the reactor: granular and cluster-like sludges. Sludge in a cluster, which involved many small granules and flocs, tended to form larger aggregates and possessed good settling ability.     

Inhibitors of Chemoresistance Pathways in Combination with Ara-C to Overcome Multidrug Resistance in AML. A Mini Review

Acute myeloid leukemia (AML), the most common type of leukemia in older adults, is a heterogeneous disease that originates from the clonal expansion of undifferentiated hematopoietic progenitor cells. These cells present a remarkable variety of genes and proteins with altered expression and function. Despite significant advances in understanding the molecular panorama of AML and the development of therapies that target mutations, survival has not improved significantly, and the therapy standard is still based on highly toxic chemotherapy, which includes cytarabine (Ara-C) and allogeneic hematopoietic cell transplantation. Approximately 60% of AML patients respond favorably to these treatments and go into complete remission; however, most eventually relapse, develop refractory disease or chemoresistance, and do not survive for more than five years. Therefore, drug resistance that initially occurs in leukemic cells (primary resistance) or that develops during or after treatment (acquired resistance) has become the main obstacle to AML treatment. In this work, the main molecules responsible for generating chemoresistance to Ara-C in AML are discussed, as well as some of the newer strategies to overcome it, such as the inclusion of molecules that can induce synergistic cytotoxicity with Ara-C (MNKI-8e, emodin, metformin and niclosamide), subtoxic concentrations of chemotherapy (PD0332991), and potently antineoplastic treatments that do not damage nonmalignant cells (heteronemin or hydroxyurea + azidothymidine).